Infectious complications after orthotopic liver transplantation

Seminars in Respiratory and Critical Care Medicine

Volumn 33, Issue 1, 2012, Pages 111-124

  Patel, Gopi ^a   Huprikar, Shirish ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

bacterial infection; cytomegalovirus; fungal infection; liver transplant

Indexed keywords

AMPHOTERICIN B; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIVIRUS AGENT; CALCINEURIN INHIBITOR; CASPOFUNGIN; CHICKENPOX VACCINE; CORTICOSTEROID; COTRIMOXAZOLE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; FLUCONAZOLE; FLUCYTOSINE; GANCICLOVIR; HEPATITIS A VACCINE; HEPATITIS B VACCINE; IMMUNOSUPPRESSIVE AGENT; INFLUENZA VACCINE; ITRACONAZOLE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MEASLES MUMPS RUBELLA VACCINE; MICAFUNGIN; PNEUMOCOCCUS VACCINE; POSACONAZOLE; RAPAMYCIN; TACROLIMUS; TUBERCULOSTATIC AGENT; UNINDEXED DRUG; VALGANCICLOVIR; VARICELLA ZOSTER VACCINE; VORICONAZOLE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL INFECTION; BILIARY TRACT DRAINAGE; BILOMA; BLOODSTREAM INFECTION; BRONCHOSCOPY; CANDIDIASIS; CHICKENPOX; CLINICAL PRACTICE; COMPUTER ASSISTED TOMOGRAPHY; CRYPTOCOCCOSIS; CYTOMEGALOVIRUS INFECTION; DEBRIDEMENT; DIFFERENTIAL DIAGNOSIS; DIPHTHERIA; DISEASE TRANSMISSION; DRUG BLOOD LEVEL; DRUG MEGADOSE; HEPATITIS A; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HERPES ZOSTER; HISTOPATHOLOGY; HOSPITAL INFECTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNIZATION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; INFECTIOUS COMPLICATION; INFLUENZA; INTENSIVE CARE; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LUNG ASPERGILLOSIS; MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY; MEASLES; MEDICAL SPECIALIST; MUCORMYCOSIS; MUMPS; MYCOSIS; MYCOTIC ANEURYSM; NEPHROTOXICITY; NUCLEIC ACID ANALYSIS; OPPORTUNISTIC INFECTION; ORGAN DONOR; ORGAN TRANSPLANTATION; ORTHOTOPIC TRANSPLANTATION; PATIENT CARE; PATIENT MONITORING; PATIENT SELECTION; PERITONITIS; PERTUSSIS; PNEUMOCOCCAL INFECTION; PNEUMOCYSTIS PNEUMONIA; POSTOPERATIVE INFECTION; PRACTICE GUIDELINE; PREOPERATIVE CARE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; RISK BENEFIT ANALYSIS; RUBELLA; SCREENING; SURGEON; SURGICAL INFECTION; SURGICAL PATIENT; TEAMWORK; TETANUS; TUBERCULOSIS; VIRUS DETECTION; VIRUS INFECTION; WOUND INFECTION;

ANTI-INFECTIVE AGENTS; CROSS INFECTION; DRUG RESISTANCE, MICROBIAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; OPPORTUNISTIC INFECTIONS; SURGICAL WOUND INFECTION;

EID: 84858740765     PISSN: 10693424     EISSN: 10989048     Source Type: Journal    
DOI: 10.1055/s-0032-1301739     Document Type: Article

References (177)

1. Fishman JA, Rubin RH. Infection in organ-transplant recipients. N Engl J Med: 1998; 338 24 1741 1751 (Pubitemid 28268592)
2. Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med: 2007; 357 25 2601 2614 (Pubitemid 350294226)
3. Kusne S, Dummer JS, Singh N., et al. Infections after liver transplantation: an analysis of 101 consecutive cases. Medicine (Baltimore): 1988; 67 2 132 143
4. Fishman JA, Issa NC. Infection in organ transplantation: risk factors and evolving patterns of infection. Infect Dis Clin North Am: 2010; 24 2 273 283
5. Singh N. Impact of current transplantation practices on the changing epidemiology of infections in transplant recipients. Lancet Infect Dis: 2003; 3 3 156 161 (Pubitemid 36278125)
6. Huprikar S. Update in infectious diseases in liver transplant recipients. Clin Liver Dis: 2007; 11 2 337 354 (Pubitemid 46992834)
7. Screening of donor and recipient prior to solid organ transplantation. Am J Transplant: 2004; 4 Suppl 10 10 20
8. Kotton CN, Ryan ET, Fishman JA. Prevention of infection in adult travelers after solid organ transplantation. Am J Transplant: 2005; 5 1 8 14 (Pubitemid 40095122)
9. Avery RK, Michaels M. Update on immunizations in solid organ transplant recipients: what clinicians need to know. Am J Transplant: 2008; 8 1 9 14
10. Guidelines for vaccination of solid organ transplant candidates and recipients. Am J Transplant: 2004; 4 Suppl 10 160 163
11. Morgan JS, Schaffner W, Stone WJ. Opportunistic strongyloidiasis in renal transplant recipients. Transplantation: 1986; 42 5 518 524 (Pubitemid 17196077)
12. DeVault GA Jr, King JW, Rohr MS, Landreneau MD, Brown ST III, McDonald JC. Opportunistic infections with Strongyloides stercoralis in renal transplantation. Rev Infect Dis: 1990; 12 4 653 671 (Pubitemid 20223416)
13. Schaeffer MW, Buell JF, Gupta M, Conway GD, Akhter SA, Wagoner LE. Strongyloides hyperinfection syndrome after heart transplantation: case report and review of the literature. J Heart Lung Transplant: 2004; 23 7 905 911 (Pubitemid 38953877)
14. Roxby AC, Gottlieb GS, Limaye AP. Strongyloidiasis in transplant patients. Clin Infect Dis: 2009; 49 9 1411 1423
15. Blair JE, Douglas DD, Mulligan DC. Early results of targeted prophylaxis for coccidioidomycosis in patients undergoing orthotopic liver transplantation within an endemic area. Transpl Infect Dis: 2003; 5 1 3 8 (Pubitemid 36705898)
16. Blair JE. Approach to the solid organ transplant patient with latent infection and disease caused by Coccidioides species. Curr Opin Infect Dis: 2008; 21 4 415 420
17. Vail GM, Young RS, Wheat LJ, Filo RS, Cornetta K, Goldman M. Incidence of histoplasmosis following allogeneic bone marrow transplant or solid organ transplant in a hyperendemic area. Transpl Infect Dis: 2002; 4 3 148 151 (Pubitemid 35364779)
18. Freifeld AG, Iwen PC, Lesiak BL, Gilroy RK, Stevens RB, Kalil AC. Histoplasmosis in solid organ transplant recipients at a large midwestern university transplant center. Transpl Infect Dis: 2005; 7 3-4 109 115 (Pubitemid 43015445)
19. Clancy CJ, Jaber RA, Leather HL., et al. Bronchoalveolar lavage galactomannan in diagnosis of invasive pulmonary aspergillosis among solid-organ transplant recipients. J Clin Microbiol: 2007; 45 6 1759 1765 (Pubitemid 46933903)
20. Fischer SA, Graham MB, Kuehnert MJ., et al. LCMV in Transplant Recipients Investigation Team. Transmission of lymphocytic choriomeningitis virus by organ transplantation. N Engl J Med: 2006; 354 21 2235 2249 (Pubitemid 43788138)
21. Iwamoto M, Jernigan DB, Guasch A., et al. West Nile Virus in Transplant Recipients Investigation Team. Transmission of West Nile virus from an organ donor to four transplant recipients. N Engl J Med: 2003; 348 22 2196 2203 (Pubitemid 36618130)
22. Srinivasan A, Burton EC, Kuehnert MJ., et al. Rabies in Transplant Recipients Investigation Team. Transmission of rabies virus from an organ donor to four transplant recipients. N Engl J Med: 2005; 352 11 1103 1111 (Pubitemid 40365351)
23. Palacios G, Druce J, Du L., et al. A new arenavirus in a cluster of fatal transplant-associated diseases. N Engl J Med: 2008; 358 10 991 998 (Pubitemid 351347098)
24. Centers for Disease Control and Prevention (CDC). Notes from the field: transplant-transmitted Balamuthia mandrillarisArizona, 2010. MMWR Morb Mortal Wkly Rep: 2010; 59 36 1182
25. Centers for Disease Control and Prevention (CDC). Balamuthia mandrillaris transmitted through organ transplantationMississippi, 2009. MMWR Morb Mortal Wkly Rep: 2010; 59 36 1165 1170
26. Centers for Disease Control and Prevention (CDC). HIV transmitted from a living organ donorNew York City, 2009. MMWR Morb Mortal Wkly Rep: 2011; 60 10 297 301
27. Ison MG, Llata E, Conover CS., et al. HIV-HCV Transplantation Transmission Investigation Team. Transmission of human immunodeficiency virus and hepatitis C virus from an organ donor to four transplant recipients. Am J Transplant: 2011; 11 6 1218 1225
28. Cohen MS, Shaw GM, McMichael AJ, Haynes BF. Acute HIV-1 infection. N Engl J Med: 2011; 364 20 1943 1954
29. Morris MI, Fischer SA, Ison MG. Infections transmitted by transplantation. Infect Dis Clin North Am: 2010; 24 2 497 514
30. Angelis M, Cooper JT, Freeman RB. Impact of donor infections on outcome of orthotopic liver transplantation. Liver Transpl: 2003; 9 5 451 462 (Pubitemid 36621712)
31. Freeman RB, Giatras I, Falagas ME., et al. Outcome of transplantation of organs procured from bacteremic donors. Transplantation: 1999; 68 8 1107 1111 (Pubitemid 29517698)
32. Lumbreras C, Sanz F, Gonzlez A., et al. Clinical significance of donor-unrecognized bacteremia in the outcome of solid-organ transplant recipients. Clin Infect Dis: 2001; 33 5 722 726 (Pubitemid 32762948)
33. Lpez-Navidad A, Domingo P, Caballero F, Gonzlez C, Santiago C. Successful transplantation of organs retrieved from donors with bacterial meningitis. Transplantation: 1997; 64 2 365 368 (Pubitemid 27332688)
34. Satoi S, Bramhall SR, Solomon M., et al. The use of liver grafts from donors with bacterial meningitis. Transplantation: 2001; 72 6 1108 1113 (Pubitemid 32924086)
35. Singh N. Impact of donor bacteremia on outcome in organ transplant recipients. Liver Transpl: 2002; 8 10 975 976
36. Singh N, Wagener MM, Obman A, Cacciarelli TV, de Vera ME, Gayowski T. Bacteremias in liver transplant recipients: shift toward gram-negative bacteria as predominant pathogens. Liver Transpl: 2004; 10 7 844 849 (Pubitemid 38979253)
37. Linares L, Garca-Goez JF, Cervera C., et al. Early bacteremia after solid organ transplantation. Transplant Proc: 2009; 41 6 2262 2264
38. Linares L, Cervera C, Hoyo I., et al. Klebsiella pneumoniae infection in solid organ transplant recipients: epidemiology and antibiotic resistance. Transplant Proc: 2010; 42 8 2941 2943
39. Shi SH, Kong HS, Xu J., et al. Multidrug resistant gram-negative bacilli as predominant bacteremic pathogens in liver transplant recipients. Transpl Infect Dis: 2009; 11 5 405 412
40. Bellier C, Bert F, Durand F., et al. Risk factors for Enterobacteriaceae bacteremia after liver transplantation. Transpl Int: 2008; 21 8 755 763
41. Bert F, Larroque B, Paugam-Burtz C., et al. Microbial epidemiology and outcome of bloodstream infections in liver transplant recipients: an analysis of 259 episodes. Liver Transpl: 2010; 16 3 393 401
42. Al-Hasan MN, Razonable RR, Eckel-Passow JE, Baddour LM. Incidence rate and outcome of Gram-negative bloodstream infection in solid organ transplant recipients. Am J Transplant: 2009; 9 4 835 843
43. Patel G, Perez F, Bonomo RA. Carbapenem-resistant Enterobacteriaceae and Acinetobacter baumannii: assessing their impact on organ transplantation. Curr Opin Organ Transplant 2010 Oct 7. [Epub ahead of print]
44. Russell DL, Flood A, Zaroda TE., et al. Outcomes of colonization with MRSA and VRE among liver transplant candidates and recipients. Am J Transplant: 2008; 8 8 1737 1743
45. Trottier V, Namias N, Pust DG., et al. Outcomes of Acinetobacter baumannii infection in critically ill surgical patients. Surg Infect (Larchmt): 2007; 8 4 437 443 (Pubitemid 47493521)
46. Reddy P, Zembower TR, Ison MG, Baker TA, Stosor V. Carbapenem-resistant Acinetobacter baumannii infections after organ transplantation. Transpl Infect Dis: 2010; 12 1 87 93
47. Patel G, Huprikar S, Factor SH, Jenkins SG, Calfee DP. Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol: 2008; 29 12 1099 1106
48. Nguyen M, Eschenauer GA, Bryan M., et al. Carbapenem-resistant Klebsiella pneumoniae bacteremia: factors correlated with clinical and microbiologic outcomes. Diagn Microbiol Infect Dis: 2010; 67 2 180 184
49. Woodford N, Dallow JW, Hill RL., et al. Ertapenem resistance among Klebsiella and Enterobacter submitted in the UK to a reference laboratory. Int J Antimicrob Agents: 2007; 29 4 456 459 (Pubitemid 46349596)
50. Lopez JA, Correa A, Navon-Venezia S., et al. Intercontinental spread from Israel to Colombia of a KPC-3-producing Klebsiella pneumoniae strain. Clin Microbiol Infect: 2011; 17 1 52 56
51. Lomaestro BM, Tobin EH, Shang W, Gootz T. The spread of Klebsiella pneumoniae carbapenemase-producing K. pneumoniae to upstate New York. Clin Infect Dis: 2006; 43 3 e26 e28
52. Kumarasamy KK, Toleman MA, Walsh TR., et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect Dis: 2010; 10 9 597 602
53. Bennett JW, Herrera ML, Lewis JS II, Wickes BW, Jorgensen JH. KPC-2-producing Enterobacter cloacae and pseudomonas putida coinfection in a liver transplant recipient. Antimicrob Agents Chemother: 2009; 53 1 292 294
54. Mathers AJ, Cox HL, Bonatti H., et al. Fatal cross infection by carbapenem-resistant Klebsiella in two liver transplant recipients. Transpl Infect Dis: 2009; 11 3 257 265
55. Sidjabat HE, Silveira FP, Potoski BA., et al. Interspecies spread of Klebsiella pneumoniae carbapenemase gene in a single patient. Clin Infect Dis: 2009; 49 11 1736 1738
56. Reid GE, Grim SA, Sankary H, Benedetti E, Oberholzer J, Clark NM. Early intra-abdominal infections associated with orthotopic liver transplantation. Transplantation: 2009; 87 11 1706 1711 10.097/TP.0b013e3181a60338
57. Lee S-O, Kang SH, Abdel-Massih RC, Brown RA, Razonable RR. Spectrum of early-onset and late-onset bacteremias after liver transplantation: implications for management. Liver Transpl: 2011; 17 6 733 741
58. Pungpapong S, Alvarez S, Hellinger WC., et al. Peritonitis after liver transplantation: incidence, risk factors, microbiology profiles, and outcome. Liver Transpl: 2006; 12 8 1244 1252 (Pubitemid 44194593)
59. Asensio A, Ramos A, Cuervas-Mons V., et al. Red de Estudio de la Infeccin en el Trasplante - Grupo de Estudio de la Infeccin en el Trasplante. Effect of antibiotic prophylaxis on the risk of surgical site infection in orthotopic liver transplant. Liver Transpl: 2008; 14 6 799 805 (Pubitemid 351895509)
60. Said A, Safdar N, Lucey MR., et al. Infected bilomas in liver transplant recipients, incidence, risk factors and implications for prevention. Am J Transplant: 2004; 4 4 574 582 (Pubitemid 38523580)
61. Safdar N, Said A, Lucey MR., et al. Infected bilomas in liver transplant recipients: clinical features, optimal management, and risk factors for mortality. Clin Infect Dis: 2004; 39 4 517 525 (Pubitemid 39120927)
62. Pappas PG, Alexander BD, Andes DR., et al. Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis: 2010; 50 8 1101 1111
63. Pappas PG, Silveira FP.; AST Infectious Diseases Community of Practice. Candida in solid organ transplant recipients. Am J Transplant: 2009; 9 Suppl 4 S173 S179
64. Neofytos D, Fishman JA, Horn D., et al. Epidemiology and outcome of invasive fungal infections in solid organ transplant recipients. Transpl Infect Dis: 2010; 12 3 220 229
65. Collins LA, Samore MH, Roberts MS., et al. Risk factors for invasive fungal infections complicating orthotopic liver transplantation. J Infect Dis: 1994; 170 3 644 652 (Pubitemid 24262267)
66. Husain S, Tollemar J, Dominguez EA., et al. Changes in the spectrum and risk factors for invasive candidiasis in liver transplant recipients: prospective, multicenter, case-controlled study. Transplantation: 2003; 75 12 2023 2029 (Pubitemid 36793286)
67. Cruciani M, Mengoli C, Malena M, Bosco O, Serpelloni G, Grossi P. Antifungal prophylaxis in liver transplant patients: a systematic review and meta-analysis. Liver Transpl: 2006; 12 5 850 858
68. Lumbreras C, Cuervas-Mons V, Jara P., et al. Randomized trial of fluconazole versus nystatin for the prophylaxis of Candida infection following liver transplantation. J Infect Dis: 1996; 174 3 583 588 (Pubitemid 26299693)
69. Winston DJ, Pakrasi A, Busuttil RW. Prophylactic fluconazole in liver transplant recipients: a randomized, double-blind, placebo-controlled trial. Ann Intern Med: 1999; 131 10 729 737 (Pubitemid 29531981)
70. Pappas PG, Kauffman CA, Andes D., et al. Infectious Diseases Society of America. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis: 2009; 48 5 503 535
71. Pappas PG, Rex JH, Sobel JD., et al. Infectious Diseases Society of America. Guidelines for treatment of candidiasis. Clin Infect Dis: 2004; 38 2 161 189 (Pubitemid 38113025)
72. Mora-Duarte J, Betts R, Rotstein C., et al. Caspofungin Invasive Candidiasis Study Group. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med: 2002; 347 25 2020 2029 (Pubitemid 35461658)
73. Reboli AC, Rotstein C, Pappas PG., et al. Anidulafungin Study Group. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med: 2007; 356 24 2472 2482 (Pubitemid 46919773)
74. Singh N, Avery RK, Munoz P., et al. Trends in risk profiles for and mortality associated with invasive aspergillosis among liver transplant recipients. Clin Infect Dis: 2003; 36 1 46 52 (Pubitemid 36099096)
75. Gustafson TL, Schaffner W, Lavely GB, Stratton CW, Johnson HK, Hutcheson RH Jr. Invasive aspergillosis in renal transplant recipients: correlation with corticosteroid therapy. J Infect Dis: 1983; 148 2 230 238 (Pubitemid 13002457)
76. Montoya JG, Chaparro SV, Celis D., et al. Invasive aspergillosis in the setting of cardiac transplantation. Clin Infect Dis: 2003; 37 Suppl 3 S281 S292 (Pubitemid 37260465)
77. Singh N, Paterson DL. Aspergillus infections in transplant recipients. Clin Microbiol Rev: 2005; 18 1 44 69 (Pubitemid 40173979)
78. Singh N, Arnow PM, Bonham A., et al. Invasive aspergillosis in liver transplant recipients in the 1990s. Transplantation: 1997; 64 5 716 720 (Pubitemid 27407098)
79. Singh N, Pruett TL, Houston S., et al. Invasive aspergillosis in the recipients of liver retransplantation. Liver Transpl: 2006; 12 8 1205 1209 (Pubitemid 44194587)
80. Singh N, Husain S.; AST Infectious Diseases Community of Practice. Invasive aspergillosis in solid organ transplant recipients. Am J Transplant: 2009; 9 Suppl 4 S180 S191
81. Fortn J, Martn-Dvila P, Moreno S., et al. Risk factors for invasive aspergillosis in liver transplant recipients. Liver Transpl: 2002; 8 11 1065 1070 (Pubitemid 35363635)
82. Gavalda J, Len O, San Juan R., et al. RESITRA (Spanish Network for Research on Infection in Transplantation). Risk factors for invasive aspergillosis in solid-organ transplant recipients: a case-control study. Clin Infect Dis: 2005; 41 1 52 59 (Pubitemid 40863744)
83. Singh N, Limaye AP, Forrest G., et al. Late-onset invasive aspergillosis in organ transplant recipients in the current era. Med Mycol: 2006; 44 5 445 449 (Pubitemid 44173328)
84. Fortn J, Martn-Davila P, Moreno S., et al. Prevention of invasive fungal infections in liver transplant recipients: the role of prophylaxis with lipid formulations of amphotericin B in high-risk patients. J Antimicrob Chemother: 2003; 52 5 813 819 (Pubitemid 37407810)
85. Fortn J, Martn-Dvila P, Montejo M., et al. GESITRA Study Group. Prophylaxis with caspofungin for invasive fungal infections in high-risk liver transplant recipients. Transplantation: 2009; 87 3 424 435
86. Paterson DL, Singh N. Invasive aspergillosis in transplant recipients. Medicine (Baltimore): 1999; 78 2 123 138 (Pubitemid 29153028)
87. Fortun J, Martin-Davila P, Alvarez ME., et al. Ramon y Cajal Hospital's Liver Transplant Group. Aspergillus antigenemia sandwich-enzyme immunoassay test as a serodiagnostic method for invasive aspergillosis in liver transplant recipients. Transplantation: 2001; 71 1 145 149 (Pubitemid 32105792)
88. Kwak EJ, Husain S, Obman A., et al. Efficacy of galactomannan antigen in the Platelia Aspergillus enzyme immunoassay for diagnosis of invasive aspergillosis in liver transplant recipients. J Clin Microbiol: 2004; 42 1 435 438 (Pubitemid 38082765)
89. Fortn J, Martn-Dvila P, Alvarez ME., et al. False-positive results of Aspergillus galactomannan antigenemia in liver transplant recipients. Transplantation: 2009; 87 2 256 260 10.1097/TP.0b013e31819288d5
90. Kawagishi N, Satoh K, Enomoto Y., et al. Risk factors and impact of beta-D glucan on invasive fungal infection for the living donor liver transplant recipients. Tohoku J Exp Med: 2006; 209 3 207 215 (Pubitemid 43905552)
91. Herbrecht R, Denning DW, Patterson TF., et al. Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillus Study Group. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med: 2002; 347 6 408 415 (Pubitemid 34851833)
92. Walsh TJ, Anaissie EJ, Denning DW., et al. Infectious Diseases Society of America. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis: 2008; 46 3 327 360 (Pubitemid 351265310)
93. Walsh TJ, Raad I, Patterson TF., et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis: 2007; 44 1 2 12 (Pubitemid 44968977)
94. Denning DW, Marr KA, Lau WM., et al. Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J Infect: 2006; 53 5 337 349 (Pubitemid 44524711)
95. Alexander BD, Perfect JR, Daly JS., et al. Posaconazole as salvage therapy in patients with invasive fungal infections after solid organ transplant. Transplantation: 2008; 86 6 791 796
96. Singh N, Limaye AP, Forrest G., et al. Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study. Transplantation: 2006; 81 3 320 326 10.1097/01.tp.0000202421.94822.f7 (Pubitemid 43255714)
97. Singh N, Wagener MM, Cacciarelli TV, Levitsky J. Antifungal management practices in liver transplant recipients. Am J Transplant: 2008; 8 2 426 431
98. Singh N, Forrest G.; AST Infectious Diseases Community of Practice. Cryptococcosis in solid organ transplant recipients. Am J Transplant: 2009; 9 Suppl 4 S192 S198
99. Husain S, Wagener MM, Singh N. Cryptococcus neoformans infection in organ transplant recipients: variables influencing clinical characteristics and outcome. Emerg Infect Dis: 2001; 7 3 375 381
100. Baddley JW, Schain DC, Gupte AA., et al. Transmission of Cryptococcus neoformans by organ transplantation. Clin Infect Dis: 2011; 52 4 e94 e98
101. Sun H-Y, Alexander BD, Lortholary O., et al. Cryptococcal Collaborative Transplant Study Group. Unrecognized pretransplant and donor-derived cryptococcal disease in organ transplant recipients. Clin Infect Dis: 2010; 51 9 1062 1069
102. Sun H-Y, Wagener MM, Singh N. Cryptococcosis in solid-organ, hematopoietic stem cell, and tissue transplant recipients: evidence-based evolving trends. Clin Infect Dis: 2009; 48 11 1566 1576
103. Sun H-Y, Alexander BD, Lortholary O., et al. Cryptococcal Collaborative Transplant Study Group. Cutaneous cryptococcosis in solid organ transplant recipients. Med Mycol: 2010; 48 6 785 791
104. Singh N, Alexander BD, Lortholary O., et al. Cryptococcal Collaborative Transplant Study Group. Cryptococcus neoformans in organ transplant recipients: impact of calcineurin-inhibitor agents on mortality. J Infect Dis: 2007; 195 5 756 764
105. Singh N, Alexander BD, Lortholary O., et al. Pulmonary cryptococcosis in solid organ transplant recipients: clinical relevance of serum cryptococcal antigen. Clin Infect Dis: 2008; 46 2 e12 e18 (Pubitemid 351269182)
106. Pappas PG, Perfect JR, Cloud GA., et al. Cryptococcus in HIV-negative patients in era of effective azole therapy. Clin Infect Dis: 2001; 33 690 699 (Pubitemid 32762943)
107. Perfect JR, Dismukes WE, Dromer F., et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis: 2010; 50 3 291 322
108. Sun H-Y, Alexander BD, Lortholary O., et al. Lipid formulations of amphotericin B significantly improve outcome in solid organ transplant recipients with central nervous system cryptococcosis. Clin Infect Dis: 2009; 49 11 1721 1728
109. Singh N, Dromer F, Perfect JR, Lortholary O. Cryptococcosis in solid organ transplant recipients: current state of the science. Clin Infect Dis: 2008; 47 10 1321 1327
110. Mueller NJ, Fishman JA. Asymptomatic pulmonary cryptococcosis in solid organ transplantation: report of four cases and review of the literature. Transpl Infect Dis: 2003; 5 3 140 143 (Pubitemid 37356357)
111. Singh N, Lortholary O, Alexander BD., et al. Antifungal management practices and evolution of infection in organ transplant recipients with cryptococcus neoformans infection. Transplantation: 2005; 80 8 1033 1039 (Pubitemid 41611924)
112. Sun H-Y, Singh N. Opportunistic infection-associated immune reconstitution syndrome in transplant recipients. Clin Infect Dis: 2011; 53 2 168 176
113. Singh N, Lortholary O, Alexander BD., et al. Cryptococcal Collaborative Transplant Study Group. An immune reconstitution syndrome-like illness associated with Cryptococcus neoformans infection in organ transplant recipients. Clin Infect Dis: 2005; 40 12 1756 1761 (Pubitemid 40799944)
114. Rodriguez M, Fishman JA. Prevention of infection due to Pneumocystis spp. in human immunodeficiency virus-negative immunocompromised patients. Clin Microbiol Rev: 2004; 17 4 770 782 (Pubitemid 39372516)
115. Radisic M, Lattes R, Chapman JF., et al. Risk factors for Pneumocystis carinii pneumonia in kidney transplant recipients: a case-control study. Transpl Infect Dis: 2003; 5 2 84 93 (Pubitemid 37221472)
116. Martin SI, Fishman JA.; AST Infectious Diseases Community of Practice. Pneumocystis pneumonia in solid organ transplant recipients. Am J Transplant: 2009; 9 Suppl 4 S227 S233
117. Kovacs JA, Hiemenz JW, Macher AM., et al. Pneumocystis carinii pneumonia: a comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies. Ann Intern Med: 1984; 100 5 663 671 (Pubitemid 14143939)
118. Sing A, Trebesius K, Roggenkamp A., et al. Evaluation of diagnostic value and epidemiological implications of PCR for Pneumocystis carinii in different immunosuppressed and immunocompetent patient groups. J Clin Microbiol: 2000; 38 4 1461 1467 (Pubitemid 30216672)
119. Hauser PM, Bille J, Lass-Flörl C., et al. Multicenter, prospective clinical evaluation of respiratory samples from subjects at risk for Pneumocystis jirovecii infection by use of a commercial real-time PCR assay. J Clin Microbiol: 2011; 49 5 1872 1878
120. Pareja JG, Garland R, Koziel H. Use of adjunctive corticosteroids in severe adult non-HIV Pneumocystis carinii pneumonia. Chest: 1998; 113 5 1215 1224 (Pubitemid 28223807)
121. Delclaux C, Zahar JR, Amraoui G., et al. Corticosteroids as adjunctive therapy for severe Pneumocystis carinii pneumonia in non-human immunodeficiency virus-infected patients: retrospective study of 31 patients. Clin Infect Dis: 1999; 29 3 670 672 (Pubitemid 29439970)
122. Mofenson LM, Brady MT, Danner SP., et al. Centers for Disease Control and Prevention; National Institutes of Health; HIV Medicine Association of the Infectious Diseases Society of America; Pediatric Infectious Diseases Society; American Academy of Pediatrics. Guidelines for the prevention and treatment of opportunistic infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics. MMWR Recomm Rep: 2009; 58 RR-11 1 166
123. Rodriguez M, Fishman JA. Prevention of infection due to Pneumocystis spp. in human immunodeficiency virus-negative immunocompromised patients. Clin Microbiol Rev: 2004; 17 4 770 782 (Pubitemid 39372516)
124. Husni RN, Gordon SM, Longworth DL., et al. Cytomegalovirus infection is a risk factor for invasive aspergillosis in lung transplant recipients. Clin Infect Dis: 1998; 26 3 753 755 (Pubitemid 28155032)
125. Freeman RB Jr. The 'indirect' effects of cytomegalovirus infection. Am J Transplant: 2009; 9 11 2453 2458
126. Kotton CN, Kumar D, Caliendo AM., et al. Transplantation Society International CMV Consensus Group. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation: 2010; 89 7 779 795 10.1097/TP.0b013e3181cee42f
127. Humar A, Snydman D.; AST Infectious Diseases Community of Practice. Cytomegalovirus in solid organ transplant recipients. Am J Transplant: 2009; 9 Suppl 4 S78 S86
128. Paya C, Humar A, Dominguez E., et al. Valganciclovir Solid Organ Transplant Study Group. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant: 2004; 4 4 611 620 (Pubitemid 38523584)
129. Small LN, Lau J, Snydman DR. Preventing post-organ transplantation cytomegalovirus disease with ganciclovir: a meta-analysis comparing prophylactic and preemptive therapies. Clin Infect Dis: 2006; 43 7 869 880 (Pubitemid 44435514)
130. Kalil AC, Levitsky J, Lyden E, Stoner J, Freifeld AG. Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med: 2005; 143 12 870 880 (Pubitemid 46202222)
131. Sun HY, Wagener MM, Singh N. Prevention of posttransplant cytomegalovirus disease and related outcomes with valganciclovir: a systematic review. Am J Transplant: 2008; 8 10 2111 2118
132. Hodson EM, Jones CA, Webster AC., et al. Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomised controlled trials. Lancet: 2005; 365 9477 2105 2115 (Pubitemid 40826968)
133. Shiley KT, Gasink LB, Barton TD, Pfeiffenberger P, Olthoff KM, Blumberg EA. Increased incidence of cytomegalovirus infection in high-risk liver transplant recipients receiving valganciclovir prophylaxis versus ganciclovir prophylaxis. Liver Transpl: 2009; 15 8 963 967
134. Arthurs SK, Eid AJ, Pedersen RA., et al. Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation. Clin Infect Dis: 2008; 46 6 840 846 (Pubitemid 351417184)
135. Singh N, Wannstedt C, Keyes L, Gayowski T, Wagener MM, Cacciarelli TV. Efficacy of valganciclovir administered as preemptive therapy for cytomegalovirus disease in liver transplant recipients: impact on viral load and late-onset cytomegalovirus disease. Transplantation: 2005; 79 1 85 90 (Pubitemid 40140005)
136. Limaye AP, Bakthavatsalam R, Kim HW., et al. Late-onset cytomegalovirus disease in liver transplant recipients despite antiviral prophylaxis. Transplantation: 2004; 78 9 1390 1396 (Pubitemid 39507981)
137. Eid AJ, Bakri SJ, Kijpittayarit S, Razonable RR. Clinical features and outcomes of cytomegalovirus retinitis after transplantation. Transpl Infect Dis: 2008; 10 1 13 18 (Pubitemid 351171315)
138. Babel N, Gabdrakhmanova L, Juergensen JS., et al. Treatment of cytomegalovirus disease with valganciclovir in renal transplant recipients: a single center experience. Transplantation: 2004; 78 2 283 285
139. Fellay J, Venetz JP, Aubert JD, Seydoux C, Pascual M, Meylan PRA. Treatment of cytomegalovirus infection or disease in solid organ transplant recipients with valganciclovir. Transplant Proc: 2005; 37 2 949 951 (Pubitemid 40590754)
140. sberg A, Humar A, Rollag H., et al. VICTOR Study Group. Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant: 2007; 7 9 2106 2113 (Pubitemid 47247057)
141. Len O, Gavald J, Aguado JM., et al. RESITRA. Valganciclovir as treatment for cytomegalovirus disease in solid organ transplant recipients. Clin Infect Dis: 2008; 46 1 20 27 (Pubitemid 351263554)
142. sberg A, Humar A, Jardine AG., et al. VICTOR Study Group. Long-term
143. Eid AJ, Arthurs SK, Deziel PJ, Wilhelm MP, Razonable RR. Clinical predictors of relapse after treatment of primary gastrointestinal cytomegalovirus disease in solid organ transplant recipients. Am J Transplant: 2010; 10 1 157 161
144. Limaye AP. Ganciclovir-resistant cytomegalovirus in organ transplant recipients. Clin Infect Dis: 2002; 35 7 866 872
145. Peleg AY, Husain S, Qureshi ZA., et al. Risk factors, clinical characteristics, and outcome of Nocardia infection in organ transplant recipients: a matched case-control study. Clin Infect Dis: 2007; 44 10 1307 1314 (Pubitemid 46717292)
146. Nocardia infections. Am J Transplant: 2004; 4 Suppl 10 47 50
147. Jodlowski TZ, Melnychuk I, Conry J. Linezolid for the treatment of Nocardia spp. infections. Ann Pharmacother: 2007; 41 10 1694 1699 (Pubitemid 47479799)
148. Moylett EH, Pacheco SE, Brown-Elliott BA., et al. Clinical experience with linezolid for the treatment of nocardia infection. Clin Infect Dis: 2003; 36 3 313 318 (Pubitemid 36169667)
149. Larruskain J, Idigoras P, Marimn JM, Prez-Trallero E. Susceptibility of 186 Nocardia sp. isolates to 20 antimicrobial agents. Antimicrob Agents Chemother: 2011; 55 6 2995 2998
150. Singh N, Paterson DL. Mycobacterium tuberculosis infection in solid-organ transplant recipients: impact and implications for management. Clin Infect Dis: 1998; 27 5 1266 1277 (Pubitemid 29242482)
151. Torre-Cisneros J, Doblas A, Aguado JM., et al. Spanish Network for Research in Infectious Diseases. Tuberculosis after solid-organ transplant: incidence, risk factors, and clinical characteristics in the RESITRA (Spanish Network of Infection in Transplantation) cohort. Clin Infect Dis: 2009; 48 12 1657 1665
152. Aguado JM, Torre-Cisneros J, Fortn J., et al. Tuberculosis in solid-organ transplant recipients: consensus statement of the group for the study of infection in transplant recipients (GESITRA) of the Spanish Society of Infectious Diseases and Clinical Microbiology. Clin Infect Dis: 2009; 48 9 1276 1284
153. Mycobacterium tuberculosis. Am J Transplant: 2004; 4 Suppl 10 37 41
154. Muoz P, Rodrguez C, Bouza E. Mycobacterium tuberculosis infection in recipients of solid organ transplants. Clin Infect Dis: 2005; 40 4 581 587 (Pubitemid 40270229)
155. Centers for Disease Control and Prevention (CDC). Transplantation- transmitted tuberculosisOklahoma and Texas, 2007. MMWR Morb Mortal Wkly Rep: 2008; 57 13 333 336
156. John GT, Shankar V, Abraham AM, Mukundan U, Thomas PP, Jacob CK. Risk factors for post-transplant tuberculosis. Kidney Int: 2001; 60 3 1148 1153 (Pubitemid 34205816)
157. Benito N, Sued O, Moreno A., et al. Diagnosis and treatment of latent tuberculosis infection in liver transplant recipients in an endemic area. Transplantation: 2002; 74 10 1381 1386 (Pubitemid 35379541)
158. Manuel O, Humar A, Preiksaitis J., et al. Comparison of quantiferon-TB gold with tuberculin skin test for detecting latent tuberculosis infection prior to liver transplantation. Am J Transplant: 2007; 7 12 2797 2801 (Pubitemid 350045785)
159. Yehia BR, Blumberg EA. Mycobacterium tuberculosis infection in liver transplantation. Liver Transpl: 2010; 16 10 1129 1135
160. Jafri S-M, Singal AG, Kaul D, Fontana RJ. Detection and management of latent tuberculosis in liver transplant patients. Liver Transpl: 2011; 17 3 306 314
161. Jahng AW, Tran T, Bui L, Joyner JL. Safety of treatment of latent tuberculosis infection in compensated cirrhotic patients during transplant candidacy period. Transplantation: 2007; 83 12 1557 1562 (Pubitemid 46987906)
162. Subramanian A, Dorman S.; AST Infectious Diseases Community of Practice. Mycobacterium tuberculosis in solid organ transplant recipients. Am J Transplant: 2009; 9 Suppl 4 S57 S62
163. Horsburgh CR Jr, Rubin EJ. Clinical practice: latent tuberculosis infection in the United States. N Engl J Med: 2011; 364 15 1441 1448
164. American Thoracic Society; CDC; Infectious Diseases Society of America. Treatment of tuberculosis. MMWR Recomm Rep: 2003; 52 RR-11 1 77
165. Holty J-EC, Gould MK, Meinke L, Keeffe EB, Ruoss SJ. Tuberculosis in liver transplant recipients: a systematic review and meta-analysis of individual patient data. Liver Transpl: 2009; 15 8 894 906
166. Schluger LK, Sheiner PA, Jonas M., et al. Isoniazid hepatotoxicity after orthotopic liver transplantation. Mt Sinai J Med: 1996; 63 5-6 364 369 (Pubitemid 26343217)
167. Meyers BR, Papanicolaou GA, Sheiner P, Emre S, Miller C. Tuberculosis in orthotopic liver transplant patients: increased toxicity of recommended agents; cure of disseminated infection with nonconventional regimens. Transplantation: 2000; 69 1 64 69 (Pubitemid 30062610)
168. Imhof A, Balajee SA, Fredricks DN, Englund JA, Marr KA. Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin Infect Dis: 2004; 39 5 743 746 (Pubitemid 39180450)
169. Marty FM, Cosimi LA, Baden LR. Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N Engl J Med: 2004; 350 9 950 952 (Pubitemid 38252550)
170. Stelzmueller I, Lass-Floerl C, Geltner C., et al. Zygomycosis and other rare filamentous fungal infections in solid organ transplant recipients. Transpl Int: 2008; 21 6 534 546 (Pubitemid 351600072)
171. Husain S, Alexander BD, Munoz P., et al. Opportunistic mycelial fungal infections in organ transplant recipients: emerging importance of non-Aspergillus mycelial fungi. Clin Infect Dis: 2003; 37 2 221 229 (Pubitemid 36930353)
172. Sun HY, Aguado JM, Bonatti H., et al. Zygomycosis Transplant Study Group. Pulmonary zygomycosis in solid organ transplant recipients in the current era. Am J Transplant: 2009; 9 9 2166 2171
173. Singh N, Aguado JM, Bonatti H., et al. Zygomycosis in solid organ transplant recipients: a prospective, matched case-control study to assess risks for disease and outcome. J Infect Dis: 2009; 200 6 1002 1011
174. Hammer GS, Bottone EJ, Hirschman SZ. Mucormycosis in a transplant recipient. Am J Clin Pathol: 1975; 64 3 389 398
175. Sun H-Y, Singh N. Mucormycosis: its contemporary face and management strategies. Lancet Infect Dis: 2011; 11 4 301 311
176. Spellberg B, Walsh TJ, Kontoyiannis DP, Edwards J Jr, Ibrahim AS. Recent advances in the management of mucormycosis: from bench to bedside. Clin Infect Dis: 2009; 48 12 1743 1751
177. Reed C, Bryant R, Ibrahim AS., et al. Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis. Clin Infect Dis: 2008; 47 3 364 371 (Pubitemid 352009357)